local coverage determination
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.
Four Years Into Foundational LCDs, Broader Reimbursement Coverage a Mixed Bag, Stakeholders Say
Premium
Palmetto GBA has expanded its decisions to cover classes of tests, rather than just one test, a move welcomed by most, but not all, of the industry.
Guardant Health Receives Medicare Coverage for Tissue-Based Cancer Test
The assay is covered under Medicare Administrative Contractor Palmetto GBA's local coverage determination for next-generation sequencing-based tests for solid tumors.
Medicare Contractor's Final Coverage Decision on NGS Cancer Testing Appeases Industry Stakeholders
Premium
The LCD covers tests that are FDA approved or cleared, have published analytical validity evidence, or are certified by a third party to be aligned with NYSDOH's criteria.
Palmetto Finalizes Medicare Coverage for MRD Cancer Testing
To receive coverage, the patient must have a personal history of cancer where the type and staging are within the intended use of the test.